The market for generic pills has gotten so bad in the U.S. that Novartis is thinking about selling off its oral solids business there, outgoing CEO Joseph Jimenez has told analysts.
The question of whether the Swiss drugmaker would ever spin off its Sandoz generics business came up during a conversation that Bernstein analysts had last week with Jimenez and drug development chief Vas Narasimhan, who will take over as CEO Feb. 1.
The CEO said that Novartis still likes the generics business outside the U.S., where he said biosimilars have given Sandoz a leading position, but it is thinking about exiting the oral solids portion of this business in the U.S. as that market continues to deteriorate, Bernstein analyst Tim Anderson recounted for clients in a note today.
“So we are examining our options, inclusive of a spin,” Jimenez told the analyst.
The company could did not respond to a request for comment.
Given that the price erosion looks to continue for some time, Sandoz is concentrating on biosimilars and complex generics, where product differentiation can provide some pricing leverage, Peter Goldschmidt, president of Sandoz U.S. and head of North America for the Swiss drugmaker said last week in his own conversation with analysts.
Generic makers across the board have been badly battered by the effects of several years of cut-throat pricing that has some drugmakers reportedly selling products at cost, leading some like Teva into major restructurings.
For Novartis, the price competition translated into a 13% generic sales decline in the U.S. in the third quarter. Sandoz reported sales of $2.6 billion, up up 1% in constant currencies, which were salvaged by 9% growth in the rest of the world.
Novartis hinted it was looking at such a move a couple of months ago when it said it would close a 450-employee generics API plant in Broomfield, Colorado.
“Novartis is currently experiencing above-average pricing pressure in our U.S. portfolio. With several products no longer competitive in saturated markets, we have made the decision to discontinue or divest these limited growth products to optimize our product portfolio,” the spokesman said at the time.
By Eric Palmer
Source: Fierce Pharma
The novel drug – named Cobenfy – introduces a new mechanism of action to the schizophrenia treatment landscape by targeting cholinergic receptors as opposed to dopamine receptors. The market for schizophrenia drugs has long been dominated by dopamine-blocking antipsychotics, which are associated with significant side effects such as Parkinsonian symptoms, sexual dysfunction, and weight gain.
The European Commission (EC) has granted marketing authorisation to Leo Pharma’s Anzupgo (delgocitinib) cream for treating adults with moderate to severe chronic hand eczema (CHE). The cream is indicated for use in CHE patients for whom topical corticosteroids are not suitable.
After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi. Quigley will start Sept. 30 as the French Big Pharma’s chief scientific officer and global head of research, Sanofi told Fierce Biotech in an emailed statement.
